Enzo Biochem base_EBIT 2024

Enzo Biochem base_EBIT

−19,54 number_format_mio USD

Enzo Biochem components_Profile_KeyStats__24

components_StockPageHeader__3

ENZ

components_StockPageHeader__4

US2941001024

components_StockPageHeader__5

865607

pages_kennzahlen_[key]_[isin]__16

pages_kennzahlen_[key]_[isin]__70

components_DataTable__24components_DataTable__3
2023−19,54
2022−12,09
20215,42
2020−23,70
2019−24,20
2018−7,10
2017−1,40
2016−3,90
2015−3,90
2014−6,30
2013−13,20
2012−12,20
2011−9,20
2010−16,70
2009−19,20
2008−9,20
2007−8,00
2006−12,80
2005−4,80
2004−5,90

Enzo Biochem Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

Enzo Biochem Inc is a US-based company operating in the biotechnology sector. It was founded in 1976 by Elazar Rabbani and is headquartered in New York. The company focuses on developing, producing, and marketing innovative diagnostic and therapeutic products for the medical industry. Enzo Biochem Inc's business model is based on the application of modern technologies for the development and synthesis of molecules for medical technology and life sciences. At the same time, the company also offers diagnostic testing systems and clinical laboratory services to its customers. Enzo Biochem's business model is therefore diverse and covers various areas. Enzo Biochem divides its business into three main segments: life sciences, clinical labs, and therapeutics. In the life sciences segment, the company engages in research and development of technologies for synthesizing molecules for medical technology. In the clinical labs segment, Enzo Biochem offers diagnostic testing systems and clinical laboratory services for use in medical diagnostics. The therapeutics segment manufactures therapeutic products for the treatment of viral infections. Enzo Biochem's product offering includes a wide range of products and services. This includes molecules for medical technology, diagnostic testing systems, and therapy products for viral infections. The product lines of Enzo Biochem include: - Molecules for medical technology: Enzo Biochem has developed a wide range of molecules for medical technology and is a leader in this field. These molecules include proteins, antibodies, and other biomolecules. The company also offers custom molecules for specific applications. - Diagnostic testing systems: The company offers a wide range of diagnostic testing systems tailored to the needs of laboratories and clinics. The tests include tests for infectious diseases, cancer, metabolic disorders, and other diseases. - Clinical laboratory services: Enzo Biochem provides a wide range of clinical laboratory services, including blood tests, microbiological tests, urine, stool, and body fluid tests, as well as histological analysis of tissue samples. - Therapy products: Enzo Biochem has developed a broad portfolio of therapy products for the treatment of viral infections. These products include immunomodulators, antivirals, and other therapeutics aimed at combating various pathogens. Enzo Biochem has made a name for itself in the biotechnology industry through continuous innovation and high-quality products. The company has also engaged in partnerships, acquisitions, and joint ventures to expand its global footprint. It has a global presence and works with leading pharmaceutical and biotech companies from around the world. Overall, Enzo Biochem has established itself as a leading biotechnology company operating in the fields of life sciences, clinical labs, and therapeutics. The company offers a wide range of products and services tailored to the needs of laboratories and clinics. Enzo Biochem has established itself as an innovation leader in the biotechnology industry and is committed to further expanding its business through the development of new products and technologies. Enzo Biochem ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__75

pages_dividenden_[isin]_index__2

components_kpi_EBITFaqs_0

components_kpi_EBITFaqs_1

components_kpi_EBITFaqs_2

components_kpi_EBITFaqs_3

components_kpi_EBITFaqs_4

components_kpi_EBITFaqs_5

components_kpi_EBITFaqs_6

components_kpi_EBITFaqs_7

components_kpi_EBITFaqs_8

components_kpi_EBITFaqs_9

components_kpi_EBITFaqs_10

components_kpi_EBITFaqs_11

components_kpi_EBITFaqs_12

components_kpi_EBITFaqs_13

components_kpi_EBITFaqs_14

components_kpi_EBITFaqs_15

components_kpi_EBITFaqs_16

components_kpi_EBITFaqs_17

components_kpi_EBITFaqs_18

components_kpi_EBITFaqs_19

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Enzo Biochem kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0

components_kpi_Savingsplan_3